Marie-Claude Fournie-Zaluski

USPTO Granted Patents = 20 (Patent Applications = 4)

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 10 (Patent Applications = 7)

Average Co-Inventor Count = 3.0

ph-index = 5

Forward Citations = 90(Granted Patents)

Company Filing History:

10 out of 1,743

Institut National De La Sante Et De La Recherche Medicale

Centre National De La Recherche Scientifique

patents

4. 1 out of 236

Hoechst Marion Roussel

Assistance Publique-hopitaux De Paris

patents

8. 1 out of 103

Université Paris Diderot-Paris 7

patents

9. 2 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1997-2018

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10131681 - Aminophosphinic derivatives that can be used in the treatment of pain (2018-11-20),

2. 9388129 - Mixed inhibitors of aminopeptidase N and neprilysin (2016-07-12),

3. 9272054 - Agents for the molecular imaging of serine-protease in human pathologies (2016-03-01),

4. 8703747 - Aminophosphinic derivatives that can be used in the treatment of pain (2014-04-22),

5. 8466309 - Amino acid derivatives, method for preparing same, and therapeutic use thereof (2013-06-18),

6. 8247609 - Aminoacid derivatives containing a disulfanyl group in the form of mixed disulfanyl and aminopeptidase N inhibitors (2012-08-21),

7. 8247608 - Aminoacid derivatives containing a disulfanyl group in the form of mixed disulfanyl and aminopeptidase N inhibitors (2012-08-21),

8. 7875436 - Peptide substrates recognizable by a botulinum toxin A, BoNT/A and the use thereof (2011-01-25),

9. 7582797 - Derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulfonates) and compositions comprising the same (2009-09-01),

10. 7264956 - Compounds and methods for inhibiting axillary malodour (2007-09-04),

11. 7235687 - Derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulfphonates) and compositions containing same (2007-06-26),

12. 7205435 - Type B botulism toxin inhibitors (2007-04-17),

13. 7169574 - Fluorescence detection of proteases or peptidases (2007-01-30),

14. 6716852 - Amino acid derivatives and use thereof as NEP, ACE and ECE inhibitors (2004-04-06),

15. 6518260 - (&agr;-aminophosphino) peptide derivatives, method for making same and therapeutic applications thereof (2003-02-11),

Certainly! Here is the article about inventor Marie-Claude Fournie-Zaluski:

Title: Innovator Spotlight: Marie-Claude Fournie-Zaluski Revolutionizing Pain Management

Introduction

Marie-Claude Fournie-Zaluski, a prolific inventor based in Paris, FR, has made significant contributions to the field of pharmacology with his groundbreaking patents. With an impressive portfolio of 20 patents, Fournie-Zaluski's work focuses on developing novel compounds for the treatment of various medical conditions, particularly in the realm of pain management.

Latest Patents

One of Fournie-Zaluski's latest patents includes the invention of Aminophosphinic derivatives, which have shown promising results in the treatment of pain, specifically neuropathic and neuroinflammatory pain. These compounds, represented by a complex formula, offer potential as medicinal products and highlight his innovative approach to addressing unmet medical needs.

Another notable patent by Fournie-Zaluski is the development of mixed inhibitors of aminopeptidase N and neprilysin. These inhibitors have shown potential for use in analgesic, anxiolytic, antidepressant, and anti-inflammatory pharmaceutical compositions, underscoring his versatility in drug discovery.

Career Highlights

Fournie-Zaluski has made significant strides in his career, with notable stints at prestigious institutions such as the Institut National De La Sante Et De La Recherche Medicale (INSERM) and Pharmaleads. His work at these research institutions has not only advanced the field of pharmacology but has also laid the foundation for novel drug development approaches.

Collaborations

Throughout his career, Fournie-Zaluski has collaborated with esteemed colleagues such as Bernard P Roques and Hervé Poras. These collaborations have been instrumental in driving innovation and fostering a conducive environment for scientific discovery.

Conclusion

Marie-Claude Fournie-Zaluski's dedication to innovating in the field of pharmacology, particularly in pain management, has positioned him as a trailblazer in the industry. With a keen focus on developing novel compounds and exploring new avenues for drug discovery, Fournie-Zaluski continues to make remarkable contributions to the field.

This text is generated by artificial intelligence and may not be accurate.